Goldman Sachs Maintains Neutral on Immunovant, Raises Price Target to $32
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $29 to $32.
Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $29 to $32.